News - Page 19 of 40

“Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.”

Roszik, J., L. E. Haydu, K. R. Hess, J. Oba, A. Y. Joon, A. E. Siroy, T. V. Karpinets, F. C. Stingo, V. Baladandayuthapani, M. T. Tetzlaff, J. A. Wargo, K. Chen, M. A. Forget, C. L. Haymaker, J. Q. Chen, F. Meric-Bernstam, A. K. Eterovic, K. R. Shaw, G. B. Mills, J. E. Gershenwald, L. G. Radvanyi, P. Hwu, P. A. Futreal, D. L. Gibbons, A. J. Lazar, C. Bernatchez, M. A. Davies and S. E. Woodman
BMC Med, 2016.

“Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression.”

Roszik, J., C. J. Wu, A. E. Siroy, A. J. Lazar, M. A. Davies, S. E. Woodman and L. N. Kwong
Sci Rep, 2016.

“Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.”

Shannan, B., Q. Chen, A. Watters, M. Perego, C. Krepler, R. Thombre, L. Li, G. Rajan, S. Peterson, P. A. Gimotty, M. Wilson, K. L. Nathanson, T. C. Gangadhar, L. M. Schuchter, A. T. Weeraratna, M. Herlyn and A. Vultur
Pigment Cell Melanoma Res, 2016.

“Heterogeneity in Melanoma (book chapter).”

Shannan, B., M. Perego, R. Somasundaram and M. Herlyn
Cancer Treat Res, 2016.

“PIM kinases as therapeutic targets against advanced melanoma.”

Shannan, B., A. Watters, Q. Chen, S. Mollin, M. Dorr, E. Meggers, X. Xu, P. A. Gimotty, M. Perego, L. Li, J. Benci, C. Krepler, P. Brafford, J. Zhang, Z. Wei, G. Zhang, Q. Liu, X. Yin, K. L. Nathanson, M. Herlyn and A. Vultur
Oncotarget, 2016.

“Oncogenic BRAF-Mediated Melanoma Cell Invasion.”

Lu, H., S. Liu, G. Zhang, L. N. Kwong, Y. Zhu, J. P. Miller, Y. Hu, W. Zhong, J. Zeng, L. Wu, C. Krepler, K. Sproesser, M. Xiao, W. Xu, G. C. Karakousis, L. M. Schuchter, J. Field, P. J. Zhang, M. Herlyn, X. Xu and W. Guo
Cell Rep, 2016.

“OMIP-031: Immunologic checkpoint expression on murine effector and memory T-cell subsets.”

Nemoto, S., A. W. Mailloux, J. Kroeger and J. J. Mule
Cytometry A, 2016.

“Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma.”

Oba, J., W. Wei, J. E. Gershenwald, M. M. Johnson, C. M. Wyatt, J. A. Ellerhorst and E. A. Grimm
Medicine (Baltimore), 2016.

“Hypoxia-driven mechanism of vemurafenib resistance in melanoma.”

Qin, Y., J. Roszik, C. Chattopadhyay, Y. Hashimoto, C. Liu, Z. A. Cooper, J. A. Wargo, P. Hwu, S. Ekmekcioglu and E. A. Grimm
Mol Cancer Ther, 2016.

“Red Hair, Light Skin, and UV-Independent Risk for Melanoma Development in Humans.”

Roider, E. M. and D. E. Fisher
JAMA Dermatol, 2016.

“MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.”

Rose, A. A., M. G. Annis, D. T. Frederick, M. Biondini, Z. Dong, L. Kwong, L. Chin, T. Keler, T. Hawthorne, I. R. Watson, K. T. Flaherty and P. M. Siegel
Clin Cancer Res, 2016.

“Targeting RRM2 and Mutant BRAF is a Novel Combinatorial Strategy for Melanoma.”

Fatkhutdinov, N., K. Sproesser, C. Krepler, Q. Liu, P. A. Brafford, M. Herlyn, K. M. Aird and R. Zhang
Mol Cancer Res, 2016.

“The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity.”

Forget, M. A., C. Haymaker, J. B. Dennison, C. Toth, S. Maiti, O. J. Fulbright, L. J. Cooper, P. Hwu, L. G. Radvanyi and C. Bernatchez
Oncoimmunology, 2016.

“Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.”

Goff, S. L., M. E. Dudley, D. E. Citrin, R. P. Somerville, J. R. Wunderlich, D. N. Danforth, D. A. Zlott, J. C. Yang, R. M. Sherry, U. S. Kammula, C. A. Klebanoff, M. S. Hughes, N. P. Restifo, M. M. Langhan, T. E. Shelton, L. Lu, M. L. Kwong, S. Ilyas, N. D. Klemen, E. C. Payabyab, K. E. Morton, M. A. Toomey, S. M. Steinberg, D. E. White and S. A. Rosenberg
J Clin Oncol, 2016.

“Immunology Comes Full Circle in Melanoma While Specific Immunity Is Unleashed to Eliminate Metastatic Disease, Inflammatory Products of Innate Immunity Promote Resistance.”

Grimm, E. A.
Crit Rev Oncog, 2016.

“Of Mice and Melanoma: PDX System for Modeling Personalized Medicine.”

Hartsough, E. J. and A. E. Aplin
Clin Cancer Res, 2016.